AN2 Therapeutics Q2 net loss widens on higher R&D costs
ANTX•Pipeline progress and 2026 outlook
The company said it is advancing three Phase 2 studies and expanding its pipeline in 2026.
AN2 expects to:
- initiate a Phase 2 trial for chronic Chagas disease in late 2026
- begin enrollment in a global Phase 2 polycythemia vera trial in the fourth quarter of 2026
- advance a second boron-based development candidate by the end of 2026
Quarterly figures and analyst view
Key details from the quarter:
| Metric | Actual |
|---|---|
| Q2 loss per share | $0.18 |
| Q2 net loss | $8.19 million |
| Q2 income from operations | -$8.90 million |
| Q2 operating expenses | $8.90 million |
The current average analyst rating on the shares is strong buy, with 2 ratings in the strong buy or buy range, no hold ratings, and no sell or strong sell ratings.
The average consensus recommendation for the biotechnology & medical research peer group is buy. Wall Street's median 12-month price target for AN2 Therapeutics Inc is , about above its Aug. 10 closing price of .
